HOME >> MEDICINE >> NEWS
National survey finds U.S. public enthusiastic about cancer screening

HANOVER, NH - The public is committed to cancer screening, even with false-positive results or the possibility that testing could lead to unnecessary treatment, according to a Dartmouth Medical School (DMS) study in the January 7 issue of The Journal of the American Medical Association (JAMA). Such enthusiasm could put the public at risk for "overtesting and overtreatment" of certain cancers, warn the researchers.

"There is growing recognition among medical professionals that cancer screening is a double-edged sword," write the investigators who include Drs. Lisa M. Schwartz and Steven Woloshin, associate professors of medicine at DMS and Dr. Gilbert Welch, professor of medicine at DMS, all of whom are physicians based at the VA Medical Center in White River Junction, VT. "While some individuals may benefit from early detection, others may only be diagnosed and treated for cancer unnecessarily. The public needs access to balanced information about its [cancer screening] potential benefits and harms."

The researchers, led by Schwartz and Woloshin, conducted national telephone interviews with 500 adults during 2001 and 2002 to learn about experience with a broad range of screening tests. The survey included 360 women aged 40 years or older and 140 men aged 50 years or older without a history of cancer. It encompassed questions about the value of early detection; and four cancer screening tests: Papanicolaou (Pap); mammography; prostate-specific antigen (PSA); and sigmoidoscopy or colonoscopy.

"Most American adults (87 percent) feel routine cancer screening is almost always a good idea," the investigators found. "Seventy-four percent believe that finding cancer early saves lives 'most' or 'all of the time.' Fifty-three percent believe screening usually reduces the amount of treatment needed when cancer is found."

The authors, who include members of the VA Outcomes Group and the Norris Cotton Cancer Center at Dartmouth, r
'"/>

Contact: Andy Nordhoff
DMS.Communications@Dartmouth.edu
603-650-1492
Dartmouth Medical School
6-Jan-2004


Page: 1 2 3

Related medicine news :

1. National Academies advisory: May 2 Symposium on International Science Policy
2. National Academies News: William H. Foege to receive Public Welfare Medal, Academys highest honor
3. National Academies news: Academy honors 17 for major contributions to science
4. National Academies advisory: Report assesses health implications of perchlorate exposure
5. National Academies Advisory: Jan. 11 public briefing on perchlorate in drinking water
6. National Academies news: Gulf War and Health
7. National survey shows few physicians elected to Congress
8. Six new Roybal Centers for Applied Gerontology established by National Institute on Aging
9. UGA professor receives $3 million grant from National Cancer Institute for breast cancer research
10. National Academies advisory: Nov. 4-6 Frontiers of Science meeting in Irvine, Calif.
11. National Chemistry Week celebrates health and wellness in Washington, D.C., area

Post Your Comments:
(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: